The Challenge: Provider Prescribing Only GLP-1s Looking to Expand Into Women’s and Men’s Bioidentical Hormone Therapies
A thriving weight-loss practice serving 50-100 patients per month, found even greater success prescribing compounded GLP-1s (semaglutide) for women and men as part of their comprehensive, personalized weight management health plans. After reading several studies about how bioidentical hormone therapy (BHRT) showed great potential for enhancing the effects of GLP-1s, and attending Belmar’s GLP-1s webinar series, the practice desired to expand into offering hormone therapies. Their goal was to further support patient success toward long-term health benefits and better patient outcomes.
While highly skilled in weight management, the providers at the practice were new to prescribing compounded hormone therapies customized for individual patient needs. They wanted to expand their services, but felt underprepared to counsel patients about hormone therapies, and were seeking education specifically to address both weight management and female patients’ symptoms of perimenopause, menopause, and male andropause, including sexual wellness.
The Solution: Partner with Belmar Pharma Solutions for Hormone Education & Compounded Therapies
The physician/owner of the weight management practice reached out to their Solutions Engineer at Belmar Pharma Solutions. The practice took advantage of Belmar’s Clinician Resources and free, on-demand educational webinars with Belmar Pharma Solutions Medical Director and world-renowned hormone expert, Angela DeRosa, DO, MBA, CPE, to begin expanding their knowledge of hormone replacement therapies for women and men.
Belmar’s clinical team worked with the providers to answer specific questions about available dosage forms and strengths for men’s and women’s hormone therapies. The clinical team also suggested that the providers learn more by enrolling in BHRT courses through one of Belmar’s educational partners: Hormonal Health Institute and Worldlink Medical Academy.
My Belmar: Successfully Expanded to Include Women’s and Men’s Bioidentical Hormone Therapies to Complement GLP-1s for a More Holistic Approach to Weight Management
Partnering with Belmar’s clinical team, taking advantage of free clinical resources, and enrolling in courses through Belmar Pharma Solutions’ preferred educational partners, allowed the thriving weight-loss practice to successfully expand their patient offerings into hormone therapies for men and women. Within a year, the practice went from only prescribing compounded semaglutide to prescribing personalized BHRT to enhance weight management, address women’s symptoms of perimenopause and menopause, and address sexual wellness and aging concerns for both men and women.
To accomplish this, the providers began prescribing compounded testosterone, estradiol, progesterone, and customized hormone combinations based on the individual needs of their patients, in conjunction with weight management medications.
As a result of this effort, patient outcomes are more comprehensive than previously, as the providers are now addressing underlying causes of weight gain, including hormonal imbalances. Many female patients who opted for compounded semaglutide in combination with personalized BHRT lost up to 30% more weight and 10% overall total body weight loss.*
Patient satisfaction has improved since patients are now experiencing both the short-term benefits of achieving their weight management goals, and the long-term health benefits of keeping the weight off and optimizing their hormones at the same time. Additionally, the practice is attracting new patients based on its expertise in hormone therapies as well as weight management.
*Read the full study: Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use.
